1. Home
  2. R&D/Manufacturing
  3. Patent Technology
  4. SBIR - R&D and innovation

Lantyng got a government fee subsidy from Small Business Innovation Research (SBIR) program: Pharmaceuticals and Biotechnology > R&D and innovation

"Preclinical Research on Antrodia cinnamomea Treatment of Metabolic syndrome and Its Mechanism"

Antrodia cinnamomea is a Taiwanese-specific fungus which has been used clinically to treat hypertension, immune- and liver-related diseases and cancer; however, it has never been studied in type 2 diabetes mellitus (T2DM). Hyperglycemia in T2DM causes endoplasmic reticulum (ER) stress, leading to β-cell dysfunction. During chronic ER stress, misfolded proteins accumulate and initiate β-cell apoptosis. Moreover, β-cell dysfunction leads to defect in insulin secretion, which is the key process in the development and progression of T2DM. We demonstrated that A. cinnamomea increased glucose-induced insulin secretion dose-dependently through peroxisome proliferator-activated receptor-γ (PPAR-γ) pathway, and upregulated genes that were involved in insulin secretion, including PPAR-γ, glucose transporter-2 and glucokinase. In conclusion, this study provided evidences that A. cinnamomea might have anti-diabetic effects and could be a novel drug for T2DM.